Cancer detection is a major public health challenge, and the methods currently available to achieve it, for example MRIs and mammograms, are often expensive and invasive.

One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells.

Chinese biotech firm SeekIn said on Thursday that it has received CE marking for its SeekInCare Cancer Detection Kit, a DNA-based blood test for early cancer detection.

Along with the development of new therapies, advances in technologies that enable earlier diagnosis of cancer are critical to improve patient outcomes.

Imagine getting a positive result on a genetic test. The doctor tells you that you have a “pathogenic genetic variant,” or a DNA sequence that is known to raise the chances for getting a disease like breast cancer or diabetes.

Pancreatic cancer is a rare, yet elusive and deadly cancer, with a five-year survival rate of about 10%. If the cancer has metastasized, that rate lowers to 3%. And treatment options are extremely limited.

Cancer diagnostics firm Oncocyte said Tuesday that it has entered into a collaboration and comarketing agreement with Thermo Fisher Scientific for two cancer in vitro diagnostic tests.

Mutations of the gene MLL4 in epithelial skin cells can inhibit healthy cell turnover and may lead to keratinocyte cancers, which collectively outnumber all other human cancers.

Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.

FDA has granted another set of regulatory privileges under its breakthrough devices program. The latest batch is led by breakthrough designations for treatments of lung cancer and bone metastases that are in development at RefleXion Medical and Zetagen Therapeutics.